Archean Chemical Q4FY26 Consolidated PAT Slumps to ₹122.3mn; FY26 Revenue Up 8% to ₹11,740.2mn
Archean Chemical Industries reported a sharp decline in Q4FY26 consolidated PAT to ₹122.3mn from ₹537.5mn YoY, with EBITDA falling to ₹490.8mn from ₹961.0mn. Full-year FY26 consolidated revenue grew 8% to ₹11,740.2mn, while PAT stood at ₹1,054.1mn versus ₹1,621.4mn in FY25. The company also highlighted a key strategic milestone—the groundbreaking of its SiC-based semiconductor facility in Bhubaneswar, approved under the Indian Semiconductor Mission, with an annual capacity of 60,000 wafers and 96 million packaging units.

*this image is generated using AI for illustrative purposes only.
Archean Chemical Industries reported a steep year-on-year decline in profitability in Q4FY26, even as full-year consolidated revenue posted modest growth. The company's Q4FY26 consolidated net profit (Profit After Tax) fell to ₹122.3mn from ₹537.5mn in Q4FY25, reflecting significant pressure on the bottom line. Consolidated total income for Q4FY26 came in at ₹3,063.3mn, compared to ₹3,533.8mn in the year-ago quarter. For the full year FY26, consolidated total income grew 8% year-on-year to ₹11,740.2mn from ₹10,912.4mn in FY25.
Q4FY26 & FY26 Consolidated Financial Performance
Operational profitability saw a sharp contraction during Q4FY26. Consolidated EBITDA declined to ₹490.8mn from ₹961.0mn on a year-on-year basis. Finance costs rose sharply to ₹104.3mn in Q4FY26 from ₹2.9mn in Q4FY25, weighing heavily on the bottom line. For the full year FY26, consolidated EBITDA stood at ₹2,657.3mn against ₹3,514.4mn in FY25, while consolidated PAT for FY26 was ₹1,054.1mn compared to ₹1,621.4mn in FY25. The following table summarizes the key consolidated financial metrics:
| Metric: | Q4FY26 | Q4FY25 | FY26 | FY25 |
|---|---|---|---|---|
| Total Income: | ₹3,063.3mn | ₹3,533.8mn | ₹11,080.0mn | ₹10,783.0mn |
| EBITDA: | ₹490.8mn | ₹961.0mn | ₹2,657.3mn | ₹3,514.4mn |
| Profit Before Tax: | ₹158.6mn | ₹746.7mn | ₹1,471.0mn | ₹2,639.5mn |
| Profit After Tax: | ₹122.3mn | ₹537.5mn | ₹1,054.1mn | ₹1,621.4mn |
| Basic EPS (₹): | 1.13 | 4.33 | 8.66 | 13.13 |
Standalone Performance
On a standalone basis, Archean Chemical's Q4FY26 total income stood at ₹3,047.1mn versus ₹3,333.3mn in Q4FY25. Standalone EBITDA for Q4FY26 came in at ₹664.0mn compared to ₹1,011.2mn in Q4FY25. Standalone PAT for Q4FY26 was ₹297.6mn, down from ₹583.1mn in Q4FY25. For the full year FY26, standalone total income was ₹10,887.5mn against ₹10,634.5mn in FY25, while standalone PAT stood at ₹1,543.7mn compared to ₹1,849.2mn in FY25.
| Metric: | Q4FY26 | Q4FY25 | FY26 | FY25 |
|---|---|---|---|---|
| Total Income: | ₹3,047.1mn | ₹3,333.3mn | ₹10,887.5mn | ₹10,634.5mn |
| EBITDA: | ₹664.0mn | ₹1,011.2mn | ₹3,080.4mn | ₹3,721.2mn |
| Profit Before Tax: | ₹419.0mn | ₹795.8mn | ₹2,102.6mn | ₹2,899.5mn |
| Profit After Tax: | ₹297.6mn | ₹583.1mn | ₹1,543.7mn | ₹1,849.2mn |
| Basic EPS (₹): | 2.41 | 4.72 | 12.51 | 14.98 |
Subsidiary-wise Revenue Contribution
The consolidated performance was supported by strong growth from subsidiaries, particularly ACUME Chemicals, which reported total income of ₹830.5mn in FY26 versus ₹274.7mn in FY25, a growth of 202% year-on-year. The parent entity ACIL contributed ₹10,887.5mn in FY26, up 2% from ₹10,634.5mn in FY25. NEUN reported income of ₹5.2mn in FY26 against ₹2.7mn in FY25, a growth of 89%.
| Entity: | FY26 Total Income | FY25 Total Income | YoY Growth |
|---|---|---|---|
| ACIL: | ₹10,887.5mn | ₹10,634.5mn | 2% |
| ACUME: | ₹830.5mn | ₹274.7mn | 202% |
| IDEALIS: | ₹17.0mn | ₹0.5mn | — |
| NEUN: | ₹5.2mn | ₹2.7mn | 89% |
| Consolidated Total Income: | ₹11,740.2mn | ₹10,912.4mn | 8% |
Silicon Carbide Semiconductor Facility: A Strategic Milestone
A key strategic development highlighted in the investor presentation is the progress on Archean's semiconductor ambitions. The company's subsidiary, SiCSem Private Limited, conducted a Bhoomi Pujan and Groundbreaking ceremony to establish an integrated Silicon Carbide (SiC)-based Compound Semiconductor fab and ATMP Unit in Info Valley, Bhubaneswar, Odisha. The facility has been approved by the Cabinet under the Indian Semiconductor Mission (ISM) and is positioned as the first commercial compound fab in the country. The project is being developed in collaboration with Clas-Sic Wafer Fab Limited, UK, in which Archean Chemical holds a 21% stake.
| Parameter: | Details |
|---|---|
| Entity: | SiCSem Private Limited (step-down subsidiary of ACIL) |
| Product: | Silicon Carbide (SiC) devices – MOSFETs and Power Devices |
| Annual Wafer Capacity: | 60,000 wafers |
| Packaging Capacity: | 96 million units |
| Location: | Info Valley, Bhubaneswar, Odisha |
| Collaboration: | Clas-Sic Wafer Fab Limited, UK (ACIL holds 21% stake) |
| End Users: | Defence, EVs, Railway, Fast Chargers, Data Centres, Consumer Appliances, Solar Power Inverters |
Consolidated Balance Sheet Highlights
As of March 26, consolidated total assets stood at ₹26,647.8mn compared to ₹23,890.3mn as of March 25. Shareholders' funds increased to ₹19,343.9mn from ₹18,640.1mn. Current borrowings rose significantly to ₹2,783.5mn from ₹264.7mn, contributing to an increase in current liabilities to ₹4,383.5mn from ₹1,972.8mn. Non-current borrowings declined to ₹1,266.7mn from ₹1,516.0mn over the same period. Cash and cash equivalents stood at ₹412.3mn as of March 26 versus ₹405.4mn as of March 25.
| Balance Sheet Item: | Mar-26 | Mar-25 |
|---|---|---|
| Total Assets: | ₹26,647.8mn | ₹23,890.3mn |
| Shareholders' Funds: | ₹19,343.9mn | ₹18,640.1mn |
| Non-Current Borrowings: | ₹1,266.7mn | ₹1,516.0mn |
| Current Borrowings: | ₹2,783.5mn | ₹264.7mn |
| Cash & Cash Equivalents: | ₹412.3mn | ₹405.4mn |
| Total Equity & Liabilities: | ₹26,647.8mn | ₹23,890.3mn |
Historical Stock Returns for Archean Chemical Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.76% | -5.57% | -4.66% | -7.48% | -0.37% | +28.12% |
How will Archean Chemical manage its significantly elevated current borrowings of ₹2,783.5mn, and what is the repayment timeline that could further pressure profitability in FY27?
Given ACUME Chemicals' 202% revenue growth in FY26, which specific product segments or geographies are driving this expansion, and can this hypergrowth trajectory be sustained?
What is the expected capital expenditure timeline and funding structure for the SiCSem SiC semiconductor fab in Bhubaneswar, and how might it impact Archean's balance sheet over the next 3-5 years?

































